welcome quarter result call operator instruction turn conference host mark vice president investor relation treasurer thank begin mark vice president investor relation treasurer good afternoon thank join today call chairman chief executive officer chief financial officer close regular trade release third quarter financial result today call management result include press release accompany financial schedule remain time please note management make forward look statement base estimate assumption projection statement include limit financial guidance expectation longer term growth opportunity regulatory approval clinical trial litigation reimbursement competitive matter foreign currency fluctuation statement speak date make undertake obligation update today additionally statement involve risk uncertainty include limit associate pandemic could cause actual result differ materially information concern factor could cause difference important product safety information find press release annual report form file available company website finally quick reminder term underlie adjust management refer financial measure otherwise refer result reconciliation number mention call include today press release like turn call comment chairman chief executive mark begin express appreciation global highly engage throughout pandemic also please supply chain remain resilient challenge time meet need patient serve turn result third quarter total company sale billion increase constant currency basis versus year period strong teen growth drive innovative platform although lower expectation significant impact hospital although experience encourage sign patient confidence continue willingness seek medical care delta variant significant impact hospital resource last month third quarter especially despite impact delta variant encourage recent decline hospital admission believe procedure unfortunately defer third quarter base expect many patient defer treatment treat future continue expect total company sale growth high teen full year third quarter global sale million dollar underlie basis versus year period estimate global procedure growth comparable growth third quarter globally average sell price remain stable sale grow year year basis estimate share procedure stable growth broad base across high volume center might expect procedure volume affect seasonality vary geography even hospital patient provider turn focus pandemic sale benefit encourage sign continue recovery pandemic however procedure negatively impact last month significant impact delta hospital resource outside third quarter sale grow approximately year year basis estimate total procedure growth comparable continue encourage strong international adoption broadly region despite impact delta market show relative resilience strong growth procedure volume growth broad base across drive continue strong adoption three ultra platform please growth rate consider center already recover pandemic longer term excellent opportunity continue growth believe global adoption therapy remain quite worth note recently publish guideline association surgery definitively recommend patient acknowledgment surgical society prefer significant development believe guideline represent important long term opportunity although transcatheter valve commercially available decade remain clear still large unmet need therapy strong adoption continue expect receive reimbursement approval treatment patient surgical risk remain focus expand availability therapy throughout country drive fact remain significantly treat disease among large elderly population upcoming meet plan late break update economic outcome partner three year summary base procedure trend expect growth similar continue expect underlie sale growth around remain confident ever long term potential transformational impact many patient suffer aortic stenosis many remain untreated long term potential reinforce view global opportunity exceed billion imply double digit compound annual growth rate turn make meaningful progress across platform patient treat date transform treatment unlock significant long term growth opportunity remain focus three value driver portfolio different shade therapy positive pivotal trial result support approval adoption favorable real world clinical outcome quarter progress enrollment five pivotal trial across portfolio support therapy patient suffer mitral tricuspid regurgitation gain experience precision platform part class trial physician feedback continue positive look forward present data class pivotal trial next year remain track approval patient late next year important milestone mark transition large single study significant pivotal trial result support approval adoption first several datasets class trial continue treat patient mitral transcatheter mitral replacement therapy pivotal trial study ramp enrollment novel tricuspid replacement therapy part pivotal trial process transfemoral therapy critical many patient without treatment option today exemplify importance comprehensive portfolio continue expand body clinical evidence look forward present meaningful data valve next month presentation include month outcome tricuspid replacement clinical trial experience study addition outcome mitral repair post market clinical follow study patient also anticipate several live case demonstration differentiate therapy turn financial performance despite impact delta summer seasonality global sale million drive continue adoption expand commercially continue experience high procedural success rate excellent clinical outcome patient remain commit employ high touch clinical support model please level site activation quarter continue expect achieve previous full year guidance million million estimate global opportunity triple approximately billion please progress toward advance vision transform life patient mitral tricuspid valve disease surgical structural heart third quarter global sale million underlie basis versus year period despite resurgence case encourage continue procedure growth across region remain encourage steady global adoption tissue valve include aortic valve valve conduit mitral valve advance tissue treatment increase support grow body real world evidence demonstrate association surgeon annual meet earlier year registry data confirm excellent real world outcome patient patient increase awareness surgical valve choice believe learn durability potential engage position choose technology summary confidence full year underlie sale growth teen surgical structural heart drive market growth adoption premium technology continue believe surgical structural heart market serve grow single digit critical care third quarter global sale million underlie basis versus year period growth drive contribution product line lead primarily strong capital sale true wave disposable pressure monitor device remain demand elevate hospitalization demand product high risk surgery also grow year year addition demand invasive finger elective procedure summary continue believe critical care grow revenue double digit range remain excite pipeline critical care innovation continue shift focus smart recovery technology design help clinician make better decision patient turn call chief financial today provide additional perspective third quarter along anticipate rest year unfold color expect investor conference total sale third quarter grow underlie basis prior year indicate earlier strong sale growth lower expect delta surge earn quarter meet expectation relate constrain spend offset lower expect sale mention base improve trend delta variant procedure trend project total sale billion billion relate product line forecast fourth quarter sale million million still potential reach underlie sale growth around full year also maintain previous range surgical structural heart critical care continue expect full year adjust earn share guidance high fourth quarter adjust cover additional detail third quarter result adjust gross profit margin period last year experience substantial respond improvement also drive profitable product partially offset negative impact foreign exchange like company sign inflation generally thing like material production ship logistics extraordinary incur last year lessen result material impact gross profit margin performance guidance broadly continue investment ensure supply chain strong resilient capable deliver life save product patient continue expect adjust gross profit margin sell general administrative expense third quarter million sale compare million prior year increase primarily drive personnel relate increase commercial activity compare impact prior year plan sequential ramp expense fourth quarter relate restriction continue subside still expect full year expense percentage sale exclude special item research development expense quarter grow prior year million sale increase primarily result continue investment transcatheter innovation include increase clinical trial activity plan increase expense fourth quarter invest develop technology generate evidence expand indication full year continue expect expense percentage sale turn report rate quarter exclude impact special item rate include basis point benefit account stock base compensation continue expect full year rate exclude special item include estimate benefit four percentage point stock base compensation account foreign exchange rate increase third quarter report sale growth basis point million compare prior year current rate continue expect approximate million positive impact full year sale compare foreign exchange rate negatively impact third quarter gross profit margin basis point compare prior year relative guidance rate positively impact third quarter earn share penny free cash flow third quarter million define cash flow operate activity million capital spend million year date free cash flow billion strong cash flow reflection exceptional portfolio patient focus technology generate return previous investment allow fund future internal external opportunity continue maintain strong flexible balance sheet approximately billion cash investment average share outstanding third quarter million continue expect average dilute share outstanding lower million guidance range approximately billion remain share repurchase program turn call back make quick comment outlook premature offer detail guidance today provide financial guidance investor conference general plan disruption assume resumption normalize sale earn growth provide guidance gross profit operate margin visibility potential impact change corporate rate back chairman chief executive please strong year date performance despite headwind associate pandemic patient clinician increasingly choose transcatheter valve therapy remain optimistic long term growth opportunity commit aggressively invest focus innovation strategy believe broad group patient still suffer structural heart disease pandemic impact wane remain confident innovative therapy result investment continue drive strong organic growth year come turn back mark mark vice president investor relation thank hear earlier investor conference take place headquarter able join campus conference host appropriate safety also available webcast either really hope part addition financial guidance hear focus innovation strategy comprehensive excite product pipeline information please visit investor relation section website ready take question reminder please limit number question plus follow allow broad participation additional question please reenter queue management answer many participant possible remainder call